FMP
Charles River Laboratories International, Inc.
CRL
NYSE
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
171.04 USD
4.11 (2.4%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
1B
1.01B
1.03B
1.01B
718.3M
660.74M
690.65M
691.37M
284.24M
349.02M
335.46M
320.19M
451.93M
199.21M
165.85M
177.22M
0
0
0
0
195.71M
199.21M
165.85M
177.22M
0
0
0
0
0
0
0
0
256.22M
0
-2.24M
5.83M
-167.69M
117.41M
169.61M
142.98M
-49.1M
-26.16M
-32M
-43.97M
-216.79M
91.24M
119.65M
99.01M
-3.04M
20.95M
25.39M
24.53M
-213.75M
68.68M
89.99M
67.33M
-4.18
1.34
1.75
1.42
-4.18
1.33
1.74
1.41
51.14M
51.39M
51.55M
51.44M
51.14M
51.58M
51.85M
51.84M
-86.45M
209.72M
238.5M
219.37M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
2.12B
2.05B
1.96B
1.89B
-213.75M
68.68M
89.99M
67.33M
-124k
-100.79M
-8.91M
-9.35M
0
0
0
0
1.81B
2.12B
2.05B
1.96B
-310.86M
-31.51M
84.87M
63.21M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
2.02B
2.03B
2B
2B
102.1M
88.2M
86.08M
85.36M
-75.62M
-38.72M
-39.49M
-79.14M
1.99B
1.98B
1.95B
2B
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-277.98M
44.9M
9.45M
-24.8M
3.12B
3.08B
3.07B
3.1B
2.85B
3.12B
3.08B
3.07B
All figures are in USD.